Mirae Asset Global Investments Co. Ltd. Purchases Shares of 1,123 ArriVent BioPharma, Inc. (NASDAQ:AVBP)

Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,123 shares of the company’s stock, valued at approximately $31,000.

Other hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new stake in ArriVent BioPharma during the fourth quarter valued at about $190,000. The Manufacturers Life Insurance Company acquired a new position in shares of ArriVent BioPharma during the third quarter valued at about $240,000. SG Americas Securities LLC acquired a new position in shares of ArriVent BioPharma during the third quarter valued at about $280,000. JPMorgan Chase & Co. raised its position in shares of ArriVent BioPharma by 183.2% during the third quarter. JPMorgan Chase & Co. now owns 12,445 shares of the company’s stock valued at $292,000 after buying an additional 8,050 shares during the last quarter. Finally, MetLife Investment Management LLC raised its position in shares of ArriVent BioPharma by 168.9% during the third quarter. MetLife Investment Management LLC now owns 16,350 shares of the company’s stock valued at $384,000 after buying an additional 10,269 shares during the last quarter. 9.48% of the stock is currently owned by institutional investors.

ArriVent BioPharma Trading Down 0.9 %

AVBP opened at $26.60 on Friday. The firm’s fifty day moving average is $26.79 and its two-hundred day moving average is $26.90. ArriVent BioPharma, Inc. has a twelve month low of $14.35 and a twelve month high of $36.37.

Analysts Set New Price Targets

Separately, HC Wainwright upped their price objective on shares of ArriVent BioPharma from $36.00 to $39.00 and gave the company a “buy” rating in a research report on Wednesday, January 22nd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $37.40.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.